Method for purifying plasmid DNA on calcium phosphate compound
AssigneeAsahi Kogaku Kogyo Kabushiki Kaisha
InventorAkira Yamamoto
Life of this patent
Estimating the term…
Loading patent…
AssigneeAsahi Kogaku Kogyo Kabushiki Kaisha
InventorAkira Yamamoto
Estimating the term…
A method is disclosed for isolating plasmid DNA, having the steps of: suspending hydroxyapatite particles in a buffer solution having a pH of about 6 to about 9, about 1 to about 100 mM of a water-soluble calcium salt and about 1 to about 100 mM of tris(hydroxymethyl) aminomethane; adding a solution containing RNA and plasmid DNA, obtained upon bacteriolysis, to the hydroxyapatite particles-containing suspension, thereby adsorbing the RNA onto the hydroxyapatite particles in the suspension; and recovering the plasmid DNA from a supernatant of the suspension. The isolation method enables effective separation of the purified plasmid DNA from a solution containing RNA and plasmid DNA in a simplified process, without the use for any special separation device.
A method for isolating plasmid deoxyribonucleic acid, comprising:
A method for isolating plasmid deoxyribonucleic acid, comprising:
Dependencies are inferred from the claim text.
No related US applications are recorded in the indexed filing history.
Drawings are temporarily unavailable. Open the PDF at USPTO
Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses…
Involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or…
Microorganisms or enzymes
Separation
Term ended 3 Sep 2017 (estimated)
USPTO file history isn’t available for this patent, so only indexed dates are shown.
1. Field of the Invention
The present invention relates to a method for isolating plasmid deoxyribonucleic acid (DNA) from nucleic acids which is one of the most basic operations in the field of genetic engineering.
2. Description of the Related Art
PBulescriptSK(+) (trademark of Stratagene) having an ampicillin-resistant gene was transformed to a JM 109 competent cell which was then cultured in a LB-agar medium containing 50 .mu.g/mL of ampicillin at 37.degree. C. for a whole day and night to obtain a single colony species. The colony species was then cultured by being shaken in an LB culture solution containing 50 .mu.g/mL of ampicillin at 37.degree. C. for a whole day and night to obtain a bacterium body. After centrifugal separation, the bacterium body was treated with an alkali-SDS method to prepare a mixed solution of plasmid DNA and RNA having a nucleic acid concentration of 200 .mu.g/mL (hereinafter, referred to as a "test solution").
A tris-calcium salt buffer solution having a pH, calcium chloride having a concentration and a buffer solution of tris(hydroxymethyl)aminomethane-hydrochloride having a concentration shown in the following Table 1 was prepared.
Thereafter, hydroxyapatite particles having an average particle diameter of about 20 microns and a specific surface area, determined in accordance with the BET method, of about 50 m.sup.2 /g, were suspended in 70 .mu.L of the tris-calcium salt buffer solution having the described pH, so that a suspension having a concentration of 10% (w/v) was obtained. Then, 10 .mu.L of the test solution was added to 0.2 mL of the obtained suspension and the suspension was shaken for five minutes at room temperature. Thereafter, a supernatant was recovered from the suspension, and then subjected to a gel electrophoretic process using 0.8% agarose gel. An analysis of the nucleic acid components was made with dying using ethidium bromide to obtain the results shown in the following Table